Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guerin and with Bacillus Calmette-Guerin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993)

Oosterlinck W., Kirkali Z., Sylvester R., da Silva F. C., Busch C., Algaba F., ...Daha Fazla

EUROPEAN UROLOGY, cilt.59, sa.3, ss.438-446, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 59 Sayı: 3
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1016/j.eururo.2010.11.038
  • Dergi Adı: EUROPEAN UROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.438-446
  • Anahtar Kelimeler: Bacillus Calmette-Guerin, Carcinoma in situ, Intravesical therapy, Mitomycin C, Non-muscle-invasive bladder cancer, Randomized clinical trial, Urinary bladder, EUROPEAN ORGANIZATION, UROTHELIAL CARCINOMA, CLINICAL-TRIALS, EAU GUIDELINES, III TRIAL, CANCER, BCG, INSTILLATION, COMBINATION, EPIRUBICIN
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: Bacillus Calmette-Guerin (BCG) is the intravesical treatment of choice for carcinoma in situ (CIS).